The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

A clinical practice guideline that stresses a multidisciplinary approach is intended to help clinicians manage obesity in ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk ...

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...